Literature DB >> 22564101

Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?

Geralyn R Spollett1.   

Abstract

PURPOSE: This article summarizes treatment regimens and issues involved in initiating insulin therapy in type 2 diabetes (T2D). Progressive deterioration of beta-cell mass and function characterizes the course of T2D. Following diet and exercise, oral antidiabetic drugs (OADs), and incretin therapies, many patients require insulin, but initiation is often delayed until complications develop. DATA SOURCES: Published guidelines for the management of T2D, primary and review articles, and Food and Drug Administration (FDA) prescribing information.
CONCLUSIONS: The diabetes nurse practitioner should encourage patients to initiate insulin when appropriate; patients need to know that this represents a natural step in treatment, not a personal failing. Initiation often occurs when OADs no longer confer adequate glycemic control. Treatment regimens available include once-daily basal insulin, sometimes with addition of prandial insulin, or premix/biphasic insulin. Insulin analogs confer less risk of hypoglycemia and weight gain, and greater dosing flexibility compared with conventional insulins. Insulin efficacy may be enhanced by continuing metformin and/or incretin therapies, while discontinuing other drugs as appropriate. IMPLICATIONS FOR PRACTICE: The well-versed diabetes nurse practitioner assists the patient in selecting the most appropriate option for his/her specific needs. It is essential to help patients overcome barriers, including fears of injection pain, public embarrassment, and hypoglycemia risk. ©2012 The Author Journal compilation ©2012 American Academy of Nurse Practitioners.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564101     DOI: 10.1111/j.1745-7599.2012.00721.x

Source DB:  PubMed          Journal:  J Am Acad Nurse Pract        ISSN: 1041-2972


  7 in total

1.  Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia.

Authors:  Ashenafi Kibret Sendekie; Achamyeleh Birhanu Teshale; Yonas Getaye Tefera
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

2.  Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Authors:  H W Rodbard; B W Bode; S B Harris; L Rose; L Lehmann; H Jarlov; J Thurman
Journal:  Diabet Med       Date:  2016-10-07       Impact factor: 4.359

Review 3.  Empowerment in the Treatment of Diabetes and Obesity.

Authors:  Włodzimierz Łuczyński; Barbara Głowińska-Olszewska; Artur Bossowski
Journal:  J Diabetes Res       Date:  2016-12-20       Impact factor: 4.011

4.  Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.

Authors:  Stephen A Brunton; Davida F Kruger; Martha M Funnell
Journal:  Clin Diabetes       Date:  2016-01

5.  Perceptions of insulin therapy in people with type 2 diabetes and physicians: a cross-sectional survey conducted in France.

Authors:  Emmanuel Cosson; Christine Mauchant; Imane Benabbad; Gilles Le Pape; Marion Le Bleis; Frédérique Bailleul; Jean-Daniel Lalau
Journal:  Patient Prefer Adherence       Date:  2019-02-11       Impact factor: 2.711

6.  [Prospective observational study of insulin detemir in patients with poorly controlled type 2 diabetes mellitus initiating insulin therapy for the first time (SOLVE Study)].

Authors:  Domingo Orozco-Beltrán; Sara Artola-Menéndez
Journal:  Aten Primaria       Date:  2015-06-06       Impact factor: 1.137

7.  Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.

Authors:  Puhong Zhang; Minyuan Chen; Heng Zhang; Yingying Luo; Dongshan Zhu; Xian Li; Jiachao Ji; Du Wang; Nadila Duolikun; Linong Ji
Journal:  BMC Endocr Disord       Date:  2022-01-19       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.